Indirect treatment comparisons of lenacapavir plus optimized background regimen versus other treatments for multidrug-resistant human immunodeficiency virus.

Chatzidaki I, Curteis T, Luedke H, et al. Value Health. 2023;26(6):810-822.

Early experience implementing long-acting injectable cabotegravir/rilpivirine for human immunodeficiency virus-1 treatment at a Ryan White-funded clinic in the US South.

Collins LF, Corbin-Johnson D, Asrat M, et al. Open Forum Infect Dis. 2022;9(9):ofac455.

Phase 3 study of ibalizumab for multidrug-resistant HIV-1.

Emu B, Fessel J, Schrader S, et al. N Engl J Med. 2018;379(7):645-654.

Boosted darunavir and dolutegravir dual therapy among a cohort of highly treatment-experienced individuals.

Hawkins KL, Montague BT, Rowan SE, et al. Antivir Ther. 2019;24(7):513-519.

48-week viral suppression rates in people with HIV starting long-acting CAB/RPV with initial viremia.

Hickey MD, Gistand N, Grochowski J, et al. Clin Infect Dis. 2024:ciae500. [Epub ahead of print]

Mechanisms of motivational interviewing for antiretroviral medication adherence in people with HIV.

Hogan A, Catley D, Goggin K, et al. AIDS Behav. 2020;24(10):2956-2965.

Fostemsavir in adults with multidrug-resistant HIV-1 infection.

Kozal M, Aberg J, Pialoux G, et al; BRIGHTE Trial Team. N Engl J Med. 2020;382(13):1232-1243.

Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.

Lataillade M, Lalezari JP, Kozal M, et al. Lancet HIV. 2020;7(11):e740-e751.

Resistance analyses in heavily treatment-experienced people with HIV treated with the novel HIV capsid inhibitor lenacapavir after 2 years.

Margot NA, Jogiraju V, Pennetzdorfer N, et al. J Infect Dis. 2025:jiaf050. [Epub ahead of print]

Assessment of second-line antiretroviral regimens for HIV therapy in Africa.

Paton NI, Kityo C, Hoppe A, et al. N Engl J Med. 2014;371(3):234-247.

Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial.

Paton NI, Kityo C, Thompson J, et al. Lancet HIV. 2017;4(8):e341-e348.

Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial.

Paton NI, Musaazi J, Kityo C, et al. Lancet HIV. 2022;9(6):e381-e393.

Long-acting injectable CAB/RPV is superior to oral ART in PWH with adherence challenges: ACTG A5359.

Rana AI, Bao Y, Zheng L, et al. Presented at: CROI; March 3-6, 2024; Denver, CO. Abstract 212.

Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen.

Santoro MM, Fornabaio C, Malena M, et al. Int J Antimicrob Agents. 2020;56(1):106027.

Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection.

Segal-Maurer S, DeJesus E, Stellbrink HJ, et al. N Engl J Med. 2022;386(19):1793-1803.

HIV: how to manage heavily treatment-experienced patients.

Spivack S, Pagkalinawan S, Samuel R, et al. Drugs Context. 2022;11:2021-9-1.